Duke Kannapolis News

This Impact Report showcases many of our accomplishments over the past year. We invite you to review these highlights and learn more about Duke CTSI’s contributions to meaningful and equitable health improvement within our communities and beyond.

With just a few clicks, a new data exploration tool developed by the Duke Clinical and Translational Science Institute (CTSI) research site in Kannapolis enables Duke investigators to quickly identify populations of interest, accelerating their research.

Svati H. Shah, MD, MHS, spoke to partners at the North Carolina Research Campus (NCRC) about the pivotal role of Duke Kannapolis at the 350-acre translational science hub focused on human health and nutrition.

During roundtable discussions with Duke collaborators, local leaders, and study participants, Duke University President Vincent Price spent his historic visit learning more about the unique research facility that has enrolled nearly 14,000 volunteers in dozens of studies using a successful community-engaged research model. Duke Kannapolis is a part of the Duke Clinical and Translational Science Institute (CTSI).

The American Journal of Translational Research (AJTR) published a paper about the methods and design of Duke CTSI’s COVID-19 research project based at Duke Kannapolis.

Project Baseline Health Study participants with prediabetes demonstrated changes in cardiac, pulmonary, and hematology measures — as well as declines in physical function and sleep — that precede diabetes. Some of these changes over four years of follow-up predicted an increased risk of progression to diabetes.

The PREVENTABLE trial is now enrolling participants at Duke Kannapolis. The study will test if taking a statin can help prevent dementia, disability, and heart disease in adults aged 75 or older.

The first publication from Duke CTSI's COVID research study based at Duke Kannapolis appears in the July 31 special issue of Diagnostics, an open access journal by MDPI. The article summarizes a pilot study with a sub-group of 100 participants in the MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study.

KANNAPOLIS, N.C.—When her lower back started to hurt, Shantela Carter joined Duke’s new study at the North Carolina Research Campus in Kannapolis.

The Duke Clinical and Translational Science Institute (CTSI) has announced a new opportunity for Duke investigators to obtain biospecimens from the MURDOCK Study for research. The MURDOCK study is a landmark longitudinal cohort of more than 12,000 diverse participants linked to clinical data and up to 14 years of outcomes data.